DOCSLIB.ORG

Taste Masking Orally Disintegrating Tablet Formulations

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Taste Masking Orally Disintegrating Tablet Formulations As appeared in July 2019 Tablets & Capsules Copyright CSC Publishing www.tabletscapsules.com orally disintegrating tablets Taste masking orally Sreeramaiah Arunkumar, disintegrating tablet formulations Vinay Muley, Michael Baumann, and Rina Chokshi DuPont Nutrition & Biosciences Orally disintegrating tablets (ODTs) are rising in popularity significant part of the global population—particularly because of their ease of administration and improved patient com- geriatric, pediatric, and psychiatric patients—has diffi- culty swallowing solid oral dosage forms (SODFs). pliance, creating the need for excipients that enable both taste ApproximatelyA 40 to 60 percent of adults living in assist- masking and rapid disintegration. This article describes a method ed-living facilities and nursing homes are reported to for taste masking ODT formulations by coating the active phar- have trouble swallowing [1,2]. And each year, approxi- maceutical ingredient (API) with an aqueous ethylcellulose mately 569,000 children, ages three to seven, also have polymer dispersion combined with different plasticizers. difficulty swallowing [3]. Others who suffer from drug-induced dysphagia or deglutition disorders face sim- ilar difficulties. When developing a new drug product, it is imperative to formulate inclusive, patient-friendly options to enable compliance. Copyright CSC Publishing Figure 1 Preparation of ECD dispersion and coating of paracetamol by fluid-bed processor (FBP) Mixing (6 hours) Mixing (30 minutes) FBP (top spray) ECD DBS PVA-PEG copolymer Preparing the dispersion Adding the Coating Curing the API granules in a tray dryer (25 percent solid based pore former the API on EC solids) Orally disintegrating tablets have most often been used for taste masking oral sus- The ODT is a patient-friendly drug delivery solution tained-release dosage forms [8]. that’s quickly rising in popularity because of its ease of This article describes a study in which researchers administration, accurate dosing, and simple storage demonstrated how to taste mask ODT formulations by requirements. The global ODT market is predicted to coating the API with an ECD polymer prior to tableting. expand at a compound annual growth rate of 11.5 per- This method of taste masking works by physically trap- cent, from $11.4 billion in 2017 to $27 billion by the end ping the porous powder in the thin, hydrophobic ECD of 2025 [4]. matrix backbone, which masks the API’s bitter taste. The Unlike other drug delivery systems and conventional hydrophobicity of ECD can then be reduced by increas- immediate-release solid dosage forms, ODTs disintegrate ing its porosity via a suitable pore former, such as polyvi- in the mouth within 5 to 30 seconds without chewing or nyl alcohol-polyethylene glycol graft copolymer. The requiring water. ODTs are popular with hospitals and coating can also help prevent gastric inactivation and healthcare providers because they yield improved com- hepatic metabolism of the API. pliance, particularly for patients whose swallowing reflex The researchers chose paracetamol as a model API is compromised, which is estimated to be up to 25 per- because of its high bitterness and ease of availability and cent of hospitalized patients [5,6]. handling. For the ECD polymer, they chose DuPont’s ODTs have also been widely supported in the pediat- Aquacoat ECD, which does not contain any plasticizer, ric realm, as the platform combines the administration so it provides formulation flexibility. By varying the sol- flexibility of a solid dosage form with the swallowability ids content of the coating formulation and combining the of a liquid dosage form [7]. ECD with different plasticizers, such as triethyl citrate In addition to disintegration time, an ODT’s organo- (TEC) or dibutyl sebacate (DBS), formulators can opti- leptic properties (taste, aftertaste, and mouthfeel) are crit- mize the tasting masking for the ODT dosage form. ical attributes because they impact patient acceptance Because DBS provides improved film performance, quick and overall medication adherence. Since most APIs are coalescence, and improved taste perception, it is an ideal bitter, sour, metallic, or otherwise unpleasant tasting, the plasticizer for preparing an ECD-based dispersion for API in an ODT must be completely taste masked while taste-masking purposes. the tablet disintegrates, especially since the ODT Coating the API remains in the mouth longer than other SODFs. The researchers first prepared the coating dispersion Taste masking ODTs by blending the ECD with the DBS plasticizer for a mini- In recent decades, the pharmaceutical industry has mum of six hours to ensure homogeneity. A 10 percent invested heavily in new technologies and made great w/w aqueous solution of polyvinyl alcohol-polyethylene strides its ability to mask unpleasant tastes and odors. As glycol graft copolymer (Kollicoat IR) was added to the a result, formulators have a broad range of format options ECD dispersion to function as a pore former, and the dis- and can now develop taste-masked drug products in the persion was stirred for an additional 30 minutes. form of granules, films, tablets, and more. For the coating trials, the researchers chose a parac- One technology that is widely used for taste masking etamol dose that was equivalent to a common clinical is the aqueous ethylcellulose dispersion (ECD). ECD dose. As shown in Figure 1, they prepared the ECD and polymers have been gaining popularity since 1958 but DBS coating dispersion (25 percent of EC solids) in a flu- Copyright CSC Publishing Table 1 Figure 2 Preparation of ECD dispersion Preparation of taste-masked paracetamol ODT tablets Amount Solid Ingredient (grams) (grams) Assumptions Aquacoat ECD 300 90 25 percent Paracetamol + Blend Alubra PG 100 + Avicel PH 105 + 10 Sucralose + Sift based on EC Pearlitol 160 C + minutes, Strawberry (#60) Plasticizer 22.5 22.5 solids Ac-Di-Sol SD 711 sieve flavor + SiO (#40) 2 Kollicoat IR 10 10 Blend Water 484.17 484.17 (10 minutes) Total coating solution 816.67 816.67 Compress into tablets (12 millimeter) idized bed processor (ACG Pharma Technologies, GPCG 1.1) using a top-spray technique that applied the Table 2 coating solution onto the paracetamol with optimized Formulation of taste-masked paracetamol tablets coating parameters. To ensure complete coalescence, the researchers cured the resultant granules for approximately 24 hours in a tray dryer with a thermal treatment at S. No. Ingredient Percentage 60°C. The percentage composition of coating solution Paracetamol granules ingredients is listed in Table 1. 1 (30 percent Aquacoat ECD+DBS) 69.15 Formulating the tablets 2 Pearlitol 160 C 20.85 The researchers then used direct compression tech- 3 Avicel PH 105 4.10 niques to formulate the ODT tablets, as shown in Figure 2. The formulation contained the taste-masked parac- 4 Ac-Di-Sol SD-711 3.00 etamol granules, mannitol (Pearlitol 160 C), microcrystal- 5 Silicon dioxide 0.30 line cellulose (Avicel PH-105) as compression aid, and 3 percent w/w croscarmellose sodium (Ac-Di-Sol SD-711) 6 Sucralose, micronized 0.50 as superdisintegrant. All ingredients were passed through 7 Strawberry flavor 0.60 a #40 sieve and mixed in a blender for 10 minutes. The selected lubricant (Alubra PG 100), flavor, sweetener, 8 Alubra PG 100 1.50 and silicon dioxide (SiO ) were then sifted through a #60 2 Total 100 sieve and added to the formulation. The researchers mixed the coated paracetamol and the ODT materials into a uniform blend and compressed the blend into tablets using 12-millimeter round punches. Figure 3 The prepared tablets were evaluated for in-process qual- ity parameters such as friability, hardness, disintegration, Taste-masking efficiency of test ODT formulation and dissolution. The percentage composition of tablet versus commercial formulation ingredients for the formulation is listed in Table 2. Conclusions Marketed paracetamol While preparing taste-masked API granules, the ODT researchers found that coating weight gain up to 25 per- cent w/w ECD-DBS dispersion yielded the most favorable Test results. The formulated tablets provided better sensory paracetamol attributes compared to a commercially available formula- ODT tion, as shown in Figure 3. As Figure 4 shows, the in vitro dissolution profile of the formulated tablet shows complete 0 1 2 3 4 drug release in less than one hour, indicating no specific Taste perception: 0 = bitter; 5 = not bitter sustained barrier to drug release. The weight variation of Copyright CSC Publishing 5. M. F. Brin and D. S. Younger. “Neurologic disorders Figure 4 and aspiration.” Otolaryngolic Clinics of North America. 1988. In vitro dissolution profile of test ODT formulation Vol. 21, pages 691-699. versus commercial formulation 6. K. A. Layne, D. S. Losinski, P. M. Zenner, and J. A. Ament. “Using the Fleming index of dysphagia to estab- lish prevalence.” Dysphagia. 1989. Vol. 4, pages 39-42. 100 7. Felipe L. Lopez, Terry B. Ernest, Catherine Tuleu and Mine Orlu Gul. “Formulation approaches to pediatric 80 oral drug delivery: benefits and limitations of current platforms.” Expert Opinion on Drug Delivery. 2015. Vol. 12, 60 No. 11, pages 1,727-1,740. 8. M. A. Frohoff-Hulsmann, A. Schmitz, and B. C. 40 Lippold, “Aqueous ethyl cellulose dispersions containing API release (%) plasticizers of different water solubility and hydroxypro- 20 Test paracetamol ODT pyl methylcellulose as coating material for diffusion pel- Marketed paracetamol ODT lets. I. Drug release rates from coated pellets.”
Load more

Recommended publications
  • An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: a Review
    Muthadi Radhika Reddy /J. Pharm. Sci. & Res. Vol. 12(7), 2020, 925-940 An Introduction to Fast Dissolving Oral Thin Film Drug Delivery Systems: A Review Muthadi Radhika Reddy1* 1School of pharmacy, Gurunanak Institute of Technical Campus, Hyderabad, Telangana, India and Department of Pharmacy, Gandhi Institute of Technology and Management University, Vizag, Andhra Pradesh, India INTRODUCTION 2. Useful in situations where rapid onset of action Fast dissolving drug delivery systems were first developed required such as in motion sickness, allergic attack, in the late 1970s as an alternative to conventional dosage coughing or asthma forms. These systems consist of solid dosage forms that 3. Has wide range of applications in pharmaceuticals, Rx disintegrate and dissolve quickly in the oral cavity without Prescriptions and OTC medications for treating pain, the need of water [1]. Fast dissolving drug delivery cough/cold, gastro-esophageal reflux disease,erectile systems include orally disintegrating tablets (ODTs) and dysfunction, sleep disorders, dietary supplements, etc oral thin films (OTFs). The Centre for Drug Evaluation [4] and Research (CDER) defines ODTs as,“a solid dosage 4. No water is required for the administration and hence form containing medicinal substances which disintegrates suitable during travelling rapidly, usually within a matter of seconds, when placed 5. Some drugs are absorbed from the mouth, pharynx upon the tongue” [2]. USFDA defines OTFs as, “a thin, and esophagus as the saliva passes down into the flexible, non-friable polymeric film strip containing one or stomach, enhancing bioavailability of drugs more dispersed active pharmaceutical ingredients which is 6. May offer improved bioavailability for poorly water intended to be placed on the tongue for rapid soluble drugs by offering large surface area as it disintegration or dissolution in the saliva prior to disintegrates and dissolves rapidly swallowing for delivery into the gastrointestinal tract” [3].
    [Show full text]
  • Comprehensive Review on Herbal Toothpaste
    Annals of R.S.C.B., ISSN:1583-6258, Vol. 25, Issue 4, 2021, Pages. 9509 - 9518 Received 05 March 2021; Accepted 01 April 2021. Comprehensive Review on Herbal Toothpaste Divya S1, Dr. J Suresh1*, Dr. S. Meenakshi 2 1. Department of Pharmacognosy, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru-570015 2.Department of Prosthodontics, JSS Dental College, JSS Academy of Higher Education &Research, Mysuru-570015 Corresponding author Dr. J. Suresh Professor Department of Pharmacognosy, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru-570015 Email: [email protected] Mobile No: 9480197611 ABSTRACT Herbal products for general as well as for oral health care have gained prominence around worldwide. People who aspire towards the use of herbal products often consider these products are relatively safer than products containing synthetic ingredients. Based on increased usage of herbal cosmetics we tried to make a comprehensive review on herbal toothpaste that helps to maintain a proper oral hygiene and free from periodontal disorder, reduce stain, gingivitis, calculus and caries. The present review gives basic information regarding antimicrobial potential of various herbs, formulationexcipients, that can be used in preparation of toothpaste. Key Words: Herbal toothpaste, Anti-microbial screening, Periodontal disorder, Gingivitis, calculus, Dental caries. INTRODUCTION In developing countries, the intensity of infections caused by certain pathogenic micro- organisms that may leads to mortality as well as morbidity in immune-suppressant patients [1]. Multiple abrasives, scent, green lead was used to remove the stain from teeth until mid- 19thcentury. In Medieval period rock salt, fine sand were the key ingredients used by Arabs for tooth cleaning.In the period 1950 AD, Dr.
    [Show full text]
  • Chapter 1 Controlling Drug Delivery
    chapter 1 Controlling drug delivery Overview In this chapter we will: & differentiate drug delivery systems according to their physical state & differentiate drug delivery systems according to their route of administration & differentiate drug delivery systems according to their type of drug release & discuss drug transport across epithelial barriers. Introduction KeyPoints & Continued developments in Pharmacotherapy can be defined as the treatment chemistry, molecular biology and prevention of illness and disease by means of and genomics support the drugs of chemical or biological origin. It ranks discovery and developments among the most important methods of medical of new drugs and new drug treatment, together with surgery, physical targets. & treatment, radiation and psychotherapy. There The drug delivery system are many success stories concerning the use of employed can control the pharmacological action of a drugs and vaccines in the treatment, prevention drug, influencing its and in some cases even eradication of diseases pharmacokinetic and (e.g. smallpox, which is currently the only subsequent therapeutic human infectious disease completely profile. eradicated). Although it is almost impossible to estimate the exact extent of the impact of pharmacotherapy on human health, there can be no doubt that pharmacotherapy, together with improved sanitation, better diet and better housing, has improved people’s health, life expectancy and quality of life. Tip Unprecedented developments in genomics Combinatorial chemistry is a way to and molecular biology today offer a plethora of build a variety of structurally related new drug targets. The use of modern chemical drug compounds rapidly and synthetic methods (such as combinatorial systematically. These are assembled chemistry) enables the syntheses of a large from a range of molecular entities number of new drug candidates in shorter times which are put together in different ‘ ’ than ever before.
    [Show full text]
  • Dissolution Testing of Orally Disintegrating Tablets
    dx.doi.org/10.14227/DT100203P6 Dissolution Testing of Orally Disintegrating Tablets James Klancke Sr. Director, Analytical Development, CIMA LABS INC, Brooklyn Park, MN email correspondence: [email protected] Abstract Orally disintegrating tablets (ODT) are solid dosage forms that disintegrate in the oral cavity leaving an easy-to-swallow residue.The disintegration times are generally less than one minute.For orally disinte- grating tablets,taste-masking of bitter or objectional-tasting drug substances is critical.The taste-masking aspect plays a significant role in dissolution method development,specifications,and testing.The USP 2 paddle apparatus is the most suitable and common choice for orally disintegrating tablets.Discriminating, robust dissolution methods are extremely useful for monitoring process optimization and changes during scale-up of taste-masked bulk drug and tablet manufacture. Introduction rally disintegrating tablets contain a wide The development of dissolution methods for variety of pharmaceutical actives covering orally disintegrating tablets is comparable to the Omany therapeutic categories,and can be approach taken for conventional tablets,and is particularly good applications for pediatric and practically identical when the orally disintegrating geriatric treatments.The time for disintegration of tablet does not utilize taste masking.The reference orally disintegrating tablets is generally considered listed drug may have dissolution conditions in a to be less than one minute [1-4],although patients USP
    [Show full text]
  • WO 2010/044736 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 April 2010 (22.04.2010) WO 2010/044736 Al (51) International Patent Classification: (74) Agents: Bratt, Henrik et al; Jarnvagsgatan 10 A, S-251 A61K 9/24 (2006.01) A61P 25/34 (2006.01) 10 Helsingborg (SE). (21) International Application Number: (81) Designated States (unless otherwise indicated, for every PCT/SE2009/05 1163 kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, (22) Date: International Filing CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, 13 October 2009 (13.10.2009) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (25) Filing Language: English HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (26) Publication Language: English ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, (30) Priority Data: NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, 0802 189-1 14 October 2008 (14.10.2008) SE SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicant (for all designated States except US): McNeil AB [SE/SE]; Box 941, S-25 1 09 Helsingborg (SE). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors; and GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (75) Inventors/Applicants (for US only): LINDELL, Katari- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, na [SE/SE]; Skarhult 1325, S-241 93 Eslδv (SE).
    [Show full text]
  • Titration of Aspirin Tablets
    Bellevue College | CHEM& 161 Titration of Aspirin Tablets In this lab, you will determine the percent purity of two commercially available aspiring tablets using an acid-base titration. In general, an acid and a base react to produce a salt and water by transferring a proton (H+): HA (aq) + NaOH (aq) H2O (l) + NaA (aq) (1) acid base salt The active ingredient in aspirin, and the chemical for which aspirin is the common name, is acetylsalicylic acid. To determine the amount of aspirin (acetylsalicylic acid) in a sample, the precise volume and concentration of the NaOH, and the overall reaction, must be known. The NaOH serves as a secondary standard, because its concentration can change over time. To find the precise concentration of the NaOH, it must be titrated against a primary standard, an acid that dissolves completely in water, has a high molar mass, that remains pure upon standing, and is not hygroscopic (tending to attract water from the air). Because sodium hydroxide is hygroscopic, it draws water from its surroundings. This mean one cannot simply weigh out a sample of sodium hydroxide, dissolve it in water, and determine the number of moles of sodium hydroxide present using the mass recorded, since any sample of sodium hydroxide is likely to be a mixture of sodium hydroxide and water. Thus, the most common way to determine the concentration of any sodium hydroxide solution is by titration. Determining the precise concentration of NaOH using a primary standard is called standardization. You will first standardize your NaOH solution, and then use it to analyze aspirin tablets for their aspirin content and purity.
    [Show full text]
  • Dosage Form Description CODE
    Dosage Form Description CODE DOSAGE_FORM DOSAGE_FORM DESCRIPTION AERO Aerosol AEPB Aerosol Powder, Breath Activated AERB Aerosol, Breath Activated AERP Aerosol, Powder AERS Aerosol, Solution AUIJ Auto-injector AJKT Auto-injector Kit BAR Bar BEAD Beads CAPS Capsule CAPA Capsule Abuse- Deterrent CPCW Capsule Chewable CPDR Capsule Delayed Release CPEP Capsule Delayed Release Particles CSDR Capsule Delayed Release Sprinkle CDPK Capsule Delayed Release Thereapy Pack C12A Capsule ER 12 Hour Abuse-Deterrent CS12 Capsule ER 12 Hour Sprinkle C2PK Capsule ER 12 Hour Therapy Pack C24A Capsule ER 24 Hour Abuse-Deterrent CS24 Capsule ER 24 Hour Sprinkle C4PK Capsule ER 24 Hour Therapy Pack CP12 Capsule Extended Release 12 Hour CP24 Capsule Extended Release 24 Hour CPEA Capsule Extended Release Abuse-Deterrent CSER Capsule Extended Release Sprinkle CEPK Capsule Extended Release Therapy Pack CPCR Capsule Extended Release* CPSP Capsule Sprinkle CPPK Capsule Therapy Pack CART Cartridge CTKT Cartridge Kit CONC Concentrate CREA Cream CRYS Crystals DEVI Device TEST Diagnostic Test DPRH Diaphragm DISK Disk ELIX Elixir EMUL Emulsion ENEM Enema EXHA Exhaler EXHL Exhaler Liquid Dosage Form Description CODE DOSAGE_FORM DOSAGE_FORM DESCRIPTION EXHP Exhaler Powder EXHS Exhaler Solution EXHU Exhaler Suspension FILM Film FLAK Flakes EXTR Fluid Extract FOAM Foam GAS Gas GEL Gel SOLG Gel Forming Solution GRAN Granules GREF Granules Effervescent GUM Gum IMPL Implant INHA Inhaler INJ Injectable INST Insert IUD Intrauterine Device JTAJ Jet-injector (Needleless) JTKT Jet-injector
    [Show full text]
  • Formulation and Evaluation of Liposomal Drug Delivery System for Doxorubicin Hydrochloride
    FORMULATION AND EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN HYDROCHLORIDE A dissertation submitted to THE TAMILNADU Dr. M.G.R.MEDICAL UNIVERSITY, CHENNAI. In partial fulfillment of the requirements for the award of degree of MASTER OF PHARMACY IN PHARMACEUTICS BY REG.NO: 26091390 Under the Guidance of Prof. S.P.SENTHIL, M.Pharm., ( Ph.D.,) OCTOBER -2011 THE ERODE COLLEGE OF PHARMACY AND RESEARCH INSTITUTE ERODE -638112, TAMILNADU DEDICATED TO My Beloved Family, Teachers & Friends CERTIFICATES The Erode College Of Pharmacy and Research Institute Prof.S.P.SENTHIL, M.Pharm.,( Ph.D.,) Department of pharmaceutics, Perundurai Main Road, Veppampalayam, Erode-638112, India. e-mail : [email protected] CERTIFICATE This is to certify that the investigation in this thesis entitled “FORMULATION AND EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN HYDROCHLORIDE” submitted to The Tamilnadu Dr. M.G.R. Medical University Chennai. For partial fulfillment of the award of degree of Master of pharmacy in Pharmaceutics was carried out by Reg. No: 26091390 in the department of pharmaceutics, The Erode College of pharmacy, Erode, under my guidance and supervision This work is original and has not been submitted in part or full to any other degree or diploma of this or any other university. Place: Erode Prof. S.P.SENTHIL, M.Pharm.,(Ph.D.,) Date: The Erode College Of Pharmacy and Research Institute Dr.V.Ganesan, M.Pharm., Ph.D., Professor and HOD of Pharmaceutics, Perundurai Main Road, Veppampalayam, Erode-638112, India. CERTIFICATE This is to certify that the investigation in this thesis entitled “FORMULATION AND EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM FOR DOXORUBICIN HYDROCHLORIDE ” submitted to the Tamil Nadu Dr.
    [Show full text]
  • Medicinal Cannabis Dosage Forms in California an Overview of Cannabis Dosage Forms
    Mica Gross President Sante Botanica / COO MDBioLogics Medicinal Cannabis Dosage Forms in California An Overview of Cannabis Dosage Forms Forms of dosage are the specific vehicles by which cannabis, or cannabinoids, are delivered into the body. Cannabis (drug-containing plant) —> The “form” in which THC and other cannabinoids Extracted Oil (drug substance) —> are administered determines how they moves and Delivery / Intake (drug product) works medicinally inside the body: ie the pharmacokinetics of cannabis. Both the plant material and the oils yielded through the extraction process influence the performance of the different forms of intake, which each have a particular set of benefits. An Overview of Cannabis Dosage Forms The medicinal effect experienced by the end- user is a function of the quality of the raw material – the cannabinoid and terpene profile of the cannabis – and of the derived oil yielded during extraction. The goal is to preserve the fidelity of the volatile medicinal compounds – such as the cannabinoids, terpenes, and flavonoids – throughout the entire chain of custody so that the therapeutic effect is intact and the dose is delivered in the most efficacious means possible. An Overview of Cannabis Dosage Forms Each form of intake is formulated to take advantage of the pharmacokinetic pathways as effectively as possible in delivering a therapeutic dose of cannabinoids (e.g. THC or CBD). An Overview of Cannabis Dosage Forms Important factors when considering each form of intake: • Bioavailability – the fraction of the administered
    [Show full text]
  • Formulation and Evaluation of Bioadhesive Tablets of Metronidazole from Gellan Gum and Gelatin
    Sylvester Okhuelegbe Eraga et al. / Journal of Pharmacy Research 2014,8(8),1132-1139 Research Article Available online through ISSN: 0974-6943 http://jprsolutions.info Formulation and evaluation of bioadhesive tablets of Metronidazole from Gellan gum and gelatin Sylvester Okhuelegbe Eraga* and Magnus Amara Iwuagwu Department of Pharmaceutics and Pharmaceutical Technology,Faculty of Pharmacy, University of Benin, PMB 1154, Benin City, 300001, Nigeria. Received on:30-06-2014; Revised on: 19-07-2014; Accepted on:09-08-2014 ABSTRACT Background: The delivery of drugs using a combination of bio-polymers is gaining extensive grounds in the development of newer drug delivery systems. In this work the formulation, evaluation and release profiles of metronidazole bioadhesive tablets formulated with admix- tures of gellan gum and gelatin were investigated. Methods: Aqueous dispersions of gellan gum and gelatin in ratios of 1:1, 1:2, 2:1, 1:4, 1:0 and 0:1 were prepared in distilled water. Metronidazole tablets were prepared with the dispersions by wet granulation. The bioadhesive strengths of the dispersions and tablets were determined using the coated bead and tensiometric methods, respectively. Tablet parameters evaluated were weight uniformity, friability, hardness, disintegration time, content of active, swelling index and tablet erosion. Release studies were carried out in simulated intestinal and gastric fluid. Results: All batches of tablets met compendial specifications with regard to weight uniformity, friability, hardness and content of active except disintegration times. Tablets prepared with gelatin alone had the highest swelling index and bioadhesive strength (40 %, 5 h and 0.253 Nm-1) while those prepared with gellan gum alone had the highest percentage tablet erosion and least bioadhesive strength (15 % and 0.085 Nm-1).
    [Show full text]
  • Aqueous Emulsion Coating for Pharmaceutical Dosage Form
    Europaisches Patentamt 0 347 024 3> European Patent Office J) Publication number: Dffice europeen des brevets 3) EUROPEAN PATENT APPLICATION © Application number: 89303290.4 © Int. CI.4: A61K 9/32 , A61K 9/36 , A61K 9/22 © Date of filing: 04.04.89 The title of the invention has been amended © Applicant: ALZA CORPORATION (Guidelines for Examination in the EPO, A-lll, 950 Page Mill Road P.O. Box 10950 7.3). Palo Alto California 94303-0802(US) © Inventor: Wong, Patrick S.-L. © Priority: 21.04.88 US 184478 2030 Cornell Street Palo Alto California 94306(US) © Date of publication of application: Inventor: Theeuwes, Felix 20.12.89 Bulletin 89/51 1634 Fallen Leaf Lane Los Altos California 94022(US) © Designated Contracting States: AT BE CH DE ES FR GB GR IT LI LU NL SE © Representative: Evans, David Charles et al F.J. CLEVELAND & COMPANY 40-43, Chancery Lane London, WC2A UQ(GB) © Aqueous emulsion coating for pharmaceutical dosage form. © A dosage form is disclosed comprising a cured emulsion coat that surrounds a drug. The emulsion comprises a lower alkyl acrylate-lower alkyl methacrylate copolymer and ethyl cellulose. The emulsion optionally comprises a hydrophilic poly- mer. eg < CM CO CL LU Xerox Copy Centre 1 EP 0 347 024 A2 2 AQUEOUS EMULSION FOR PHARMACEUTICAL DOSAGE FORM This invention pertains to a pharmaceutical final dosage form. dosage form comprising an aqueous emulsion coat It will be appreciated by those skilled in the and to an aqueous emulsion coat. drug dispensing art that if a coating is provided that is substantially free of organic solvents when coat- 5 ing drugs, drug granules, drug powders, drug dis- BACKGROUND OF THE INVENTION pensers, and the like, such a coating would have an immediate positive value and, concomitantly, represent an advancement in the drug coating art.
    [Show full text]
  • Draft Guidance on Nicotine Active Ingredient
    Contains Nonbinding Recommendations Draft Guidance on Nicotine This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Nicotine Dosage Form; Route: Film, extended release; transdermal Recommended Studies: Three studies 1. Type of study: Bioequivalence (BE) study with pharmacokinetic (PK) endpoints Design: Single-dose, two-treatment, two-period crossover in vivo Strength: 21 mg/24 hr Subjects: Males and non-pregnant, non-lactating females, smokers Additional comments: In this document, this dosage form is referred to as a transdermal delivery system (TDS) and includes products that may be described elsewhere or known as patches or extended release films. Unless otherwise justified, the nicotine TDS should be applied to the same anatomical site on all subjects, selected from among those recommended for dosing in the approved labeling for the reference listed drug (RLD) product, and worn for 24 hours. Applicants should randomize subjects to receive either the test or RLD product in a given study period. When possible, the TDS administered in the second study period should be applied to the same anatomical site as in the first study period, but on the contralateral side of the body. Contact of the TDS with the skin is essential for the in vivo performance of the TDS, and the PK may be altered when a TDS loses its adherence to the skin.
    [Show full text]